TrialRadiation oncology (London, England)2011

Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.

Lucie Oberic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.